



The Effect of Sildenafil Citrate on Improving Amniotic Fluid Index in Pregnant Women with Oligohydramnios and Borderline Oligohydramnios: A Randomized Controlled Trial

Shahla Nasrolahi¹, Elaheh Talebi-Ghane² and Leila Torkashvand^{1*}

¹Clinical Research Development Unit of Fatemeh Hospital, Department of Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

²Modeling of Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

*Corresponding author: Clinical Research Development Unit of Fatemeh Hospital, Department of Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Email: torkashvand.leila23@gmail.com

Received 2023 January 18; Revised 2023 June 07; Accepted 2023 June 21.

Abstract

Background: Oligohydramnios is a common problem in pregnancy that requires therapeutic measures in addition to managing the underlying cause.

Objectives: This study aimed to assess sildenafil citrate's impact on the amniotic fluid index in pregnant women with oligohydramnios and borderline oligohydramnios.

Methods: Women with a singleton pregnancy, oligohydramnios, and gestational age of 24 to 36 weeks were included. Patients were randomly divided into two groups. The intervention group also received 50 mg of sildenafil citrate every 8 hours and 3 liters of isotonic solution per day. In the control group, a placebo was given along with hydration therapy, similar to the intervention groups. The amount of amniotic fluid was reassessed one week and two weeks after treatment. Weekly measurements of amniotic fluid volume, biophysical profile, and non-stress test were used twice a week for fetal monitoring. This study analyzed the data using SPSS version 23 with a significance threshold of $P \leq 0.05$.

Results: Finally, there was a substantial change in the amniotic fluid level between the basic and end of the second week ($P \leq 0.05$). There was no apparent distinction between the two groups regarding pharmaceutical side effects or the consequences of pregnancy.

Conclusions: Sildenafil citrate enhanced amniotic fluid production, although no significant issues were seen for the mother or fetus.

Keywords: Oligohydramnios, Amniotic Fluid Index, Sildenafil Citrate

1. Background

Amniotic fluid surrounds the fetus during development and serves a variety of functions, such as safeguarding the fetus when the mother's abdomen sustains damage by providing a cushion between the fetus and the umbilical cord. Amniotic fluid also safeguards the umbilical cord and lessens the possibility of uterine wall compression (1). Amniotic fluid's antimicrobial properties aid in protecting the fetus from pathogenic pathogens. Furthermore, fluid and nutrition are stored for the fetus to hold the proteins, electrolytes, immunoglobulins, and vitamins. This fluid supplies the environment and essential growth factors for the fetal organs, including the musculoskeletal, digestive, and pulmonary systems, normal growth, and maturation. Doctors can use amniotic

fluid to track a pregnancy's development and forecast fetal outcomes (2).

A woman's amniotic sac is determined by how much fluid enters and leaves. Late pregnancy, swallowing, fetal urination, and lung fluid expulsion significantly contribute to fluid transport, with little help from other sources (3, 4). The amniotic fluid volume changes due to fetal abnormalities that affect any of these functions. As an illustration, growth-restricted fetuses might redistribute blood flow away from their kidneys, which lowers fetal urine production and causes oligohydramnios (5).

A lack of amniotic fluid, or oligohydramnios, can negatively affect the pregnancy's prognosis because amniotic fluid is crucial for maintaining fetal health (6). Low amniotic fluid volume is linked to a higher fetal

and neonatal mortality rate and morbidity (7). Many studies have recorded neonatal intensive care unit (NICU) hospitalization, cesarean sections owing to fetal distress, meconium aspiration syndrome, fetal growth limitation, premature birth, and even fetal mortality in pregnancies with oligohydramnios (8-10).

Oligohydramnios is described as an amniotic fluid index (AFI) of 5 cm or less (9), while borderline (marginal) oligohydramnios is defined as an AFI of 5.1 to 8.0 cm (11, 12). In a study on 89050 healthy pregnancies with a singular and non-anomalous fetus at term, oligohydramnios (identified as $AFI \leq 5$ cm) was found in 4.4% of the cases (13).

Utero-placental perfusion is increased by sildenafil citrate, a phosphodiesterase type 5 inhibitor (14). Increased uterine blood flow and amplified estrogen-induced vasodilation are the effects of sildenafil citrate (15). Two comprehensive clinical evaluations examined whether sildenafil citrate is safe to use while pregnant. Both trials found that minor maternal side effects, such as headaches, flushing, vision disturbances, dizziness, palpitations, arthralgia, dyspepsia, and epigastric discomfort, were not more common than with placebo (16, 17).

Studying sildenafil citrate is necessary to determine its safety and effectiveness in treating oligohydramnios. In contrast, previous clinical evaluations have found that sildenafil citrate is generally safe for pregnant women and may increase uterine blood flow. Hence, further research is needed to fully understand its potential benefits and risks in treating oligohydramnios. A well-designed study could provide more definitive evidence on the safety and effectiveness of sildenafil citrate for this purpose.

2. Objectives

The current study aimed to evaluate sildenafil's effect on the volume of amniotic fluid in women who had oligohydramnios or borderline oligohydramnios.

3. Methods

3.1. Study Design

Pregnant women diagnosed with oligohydramnios or borderline oligohydramnios participated in this research experiment at Fatemeh Training Hospital in Hamedan, Iran. Women with a singleton pregnancy and gestational age between 24 and 36 weeks diagnosed with borderline oligohydramnios or oligohydramnios (average amniotic fluid index less than 8 cm, determined

by transabdominal ultrasound) were included. Patients with preeclampsia, treated with anti-hypertensive drugs, or allergic to sildenafil citrate were excluded. Informed consent was obtained from each participant before enrolling in the study, and patients were included in the study only if they met the eligibility criteria and consented to participate in the clinical trial. The trial was documented in the Iran Registry of Clinical Trials (IRCT) (IRCT20220903055868N1). The study was approved by the Hamedan University of Medical Sciences Ethics Committee (IR.UMSHA.REC.1401.361). The hiring process began in October 2022.

According to this study, 42 women hospitalized in Fatemeh Hospital were divided into two groups. Group A was assigned to the case group, and Group B was related to the placebo group. Block randomization and classification were used to ensure the equality of the two groups in terms of the number and variables affecting the study results. Both groups were the same in terms of maternal age and gestational age. This study is double-blind, so the researcher and the subject needed to be made aware of the allocation status of the groups. Since the drug is prescribed together with other medications. Therefore, the issue is unaware of the status of allocation to the groups, and the researcher who measures the clinical and diagnostic measurements was unaware of the individuals' status. A supervisor is mindful of the allocation of groups. Sealed and hidden envelopes were used during random distribution. Additionally, a statistician unaware of the study's groups conducted the study's statistical analysis.

The primary amniotic fluid index of the patients was measured when hospitalized. In the intervention group, 3 liters of isotonic solution (Ringer lactate) were administered intravenously every 24 hours with 50 mg of oral sildenafil citrate (Pharma Chemistry-Iran) every 8 hours and hydration treatment, and a placebo was given to the control group. Betamethasone injections were given to women whose gestational age was less than $36 + 6$ weeks. The amniotic fluid index was remeasured one and two weeks after the intervention. The woman was released if an ultrasound revealed a rise in the amniotic liquid index of at least 8 cm.

3.2. Data Collection Tools

A nonstress test (NST) was used to check the fetus's health twice a week. At the same time, biophysical profiles and measurements of the amniotic fluid volume by abdominal ultrasonography were performed once a week.

The frequency of maternal pregnancy termination and side effects of the drug were investigated and compared.

3.3. Statistical Analysis

Statistical analysis of the data was performed using SPSS version 23. The significance threshold was deemed to be 0.05 or lower. The mean and standard deviation were used to describe quantitative data, whereas frequency and percentages were used to display qualitative data. The *t*-test or Mann-Whitney test was used to analyze quantitative variables between the two groups statistically. In contrast, the chi-square or Fisher test was used for the statistical analysis of qualitative data. The Friedman test was used to compare the amniotic index three times. A 95% confidence interval odds ratio and the logistic regression test were performed to assess the effects.

4. Results

A total of 42 women participated in this study; 3 in the intervention group and 5 in the control group were terminated during the survey. As shown in [Table 1](#), maternal age, gestational age, and amniotic fluid index before the intervention are not significantly different between the two groups (P -value > 0.05).

Average indices were compared in two groups three times (at the primary, after 1st week, and 2nd week after treatment). Additionally, the amount of increased amniotic fluid in each group was examined.

According to [Table 2](#), the amniotic fluid was not significantly different between the two groups during the primary, after 1st week, and 2nd week after treatment (P -value > 0.05). However, there was a considerable variation in the study group's amniotic fluid levels from primary to two weeks after treatment (P -value < 0.05). As considered in [Table 2](#), the amniotic fluid levels were increased over time in two groups.

During the first and second weeks, the amniotic fluid change was compared between the two groups. Over one week, neither group's amniotic fluid index increases significantly (all P -values > 0.05). This change was significant at the end of two weeks. A significant difference was noted between the amniotic fluid index of the intervention group and its primary index during hospitalization compared to the control group ([Table 3](#) and [Figure 1](#)).

There was no significant difference between the two groups regarding pharmacological side effects (all P -value > 0.05) ([Table 4](#)).

5. Discussion

The results demonstrated that sildenafil citrate and hydration, compared to hydration alone, can improve AFI

without causing negative side effects and is an effective treatment option. Currently, various techniques are used to treat and control oligohydramnios. Amnioinfusion is an invasive method with potential risks of increasing the amount of amniotic fluid (18). Maternal hydration techniques can also improve amniotic fluid, but it is not yet clear how AFI changes following maternal hydration and how long these changes last (19, 20). The oral sildenafil administration method is non-invasive and safer, resulting in fewer complications and more patient comfort.

Sildenafil was shown to be effective at reducing AFI in our research, but we did not investigate the exact mechanism by which it may have such an effect. Vasodilation was proposed to be brought on by sildenafil, which may enhance uteroplacental perfusion, raising fetal renal blood flow, fetal urine output, and AFI (21). This increase in AFI improved pregnancy and neonatal outcomes.

The results of this study are consistent with those of Choudhary et al.'s study, which reported a significant increase in the amniotic fluid index following the use of sildenafil citrate during pregnancy, and no specific side effects for the mother or fetus were reported (22). In addition, Maher et al. showed that administration of sildenafil citrate and intravenous hydration is associated with greater amniotic fluid volume with more prolonged pregnancy compared to hydration alone (23). Nath et al. indicated that patients with oligohydramnios could significantly improve with sildenafil citrate (24). In line with Dunn et al., in the current study, women who used sildenafil citrate did not experience any significant negative effects and confirmed the safety of this treatment (16).

The following are some of the positive aspects of the research: (1) an appropriate randomization procedure was used; (2) a power analysis was conducted; (3) continuous or temporary increases in AFI were measured, and the mother and fetus were continuously monitored during the study; (4) the participants' gestational ages ranged from 24 to 36 weeks, which represents a considerable variation; (5) the clinical significance of improving AFI was evaluated; and (6) the control group was given a placebo.

Nevertheless, some negative aspects remain, including the following: (1) despite our best efforts, the results should be interpreted cautiously because measuring AFI is subjective and challenging due to fetal movement. There is a poor correlation between ultrasonography and actual amniotic fluid volume. Hence, such obstacles were overcome by selecting an ultrasonographer blinded to the treatment arms; (2) pregnancies that were considered normal before 24 weeks of gestation and pregnancies

Table 1. Comparison of Baseline Characteristics Between the Two Groups

	Sildenafil		Placebo		P-Value ^a
	Count	Mean ± SD	Count	Mean ± SD	
Age	21	25.24 ± 6.69	21	26.60 ± 7.50	0.539
Gestational age	21	30.43 ± 2.46	21	31.00 ± 2.43	0.453
Basic amniotic fluid	21	5.24 ± 1.18	16	5.52 ± 1.03	0.413

Abbreviation: SD, standard deviation.

^a Independent t-test.**Table 2.** Amniotic Fluid Index in the Two Groups After Treatment

AFI	Sildenafil		Placebo		P-Value
	Count	Mean ± SD	Count	Mean ± SD	
Basic	21	5.24 ± 1.18	21	5.52 ± 1.03	0.413 ^a
After 1st week	21	5.81 ± 0.93	21	5.90 ± 0.77	0.669 ^a
After 2nd week	18	7.06 ± 2.15	16	6.06 ± 1.14	0.097 ^b
P-value ^c	0.006		0.232		

Abbreviations: AFI, amniotic fluid index; SD, standard deviation.

^a Mann-Whitney.^b Independent t-test.^c Friedman test.**Table 3.** Comparison of Amniotic Fluid Index Increase in Both Groups After Treatment

AFI	Sildenafil		Placebo		P-Value ^a
	Count	Mean ± SD	Count	Mean ± SD	
After 1st week- basic	21	0.57 ± 0.93	21	0.38 ± 1.47	0.630
After 2nd week- basic	18	1.78 ± 1.86	16	0.59 ± 1.33	0.048

Abbreviations: AFI, amniotic fluid index; SD, standard deviation.

^a Independent t-test.**Table 4.** Comparison of Drug Side Effects and Termination of Pregnancy in Both Groups^a

	Sildenafil	Placebo	P-Value ^b
Side effects			0.488
No	19 (90.5)	21 (100.0)	
Yes	2 (9.5)	0 (0.0)	
Termination of pregnancy			0.697
No	18 (85.7)	16 (76.2)	
Yes	3 (14.3)	5 (23.8)	

^a Values are expressed as No. (%).^b Exact Fisher test.

and complicated for either the mother or the fetus were excluded; (3) since the mother's posture was not standardized throughout hospital treatment, its effect on changes in AFI rates is unclear; (4) features of amniotic fluid, such as the solute contents after therapy, were not

investigated. In contrast to real amniotic fluid volume, AFI parameters were used to measure improvement after treatment; (5) the circulating plasma volume rises during pregnancy, which may modify the pharmacokinetics of the medication. However, data on pregnancy are restricted, so it is difficult to determine an appropriate dose of sildenafil or a dosage and administration schedule. Taking 100 mg of sildenafil orally results in a plasma concentration of more than 100nmol/L for 4 - 5 hours, which is 100 times lower than the concentration needed for nonspecific inhibition of other phosphodiesterase (PDE) isoforms.

5.1. Conclusions

Based on the results, sildenafil citrate consistently increased AFI without causing negative embryonic consequences. Future studies should consider more samples, the outcome of the newborn, including the Apgar score of the newborn and the hospitalization rate of the newborn in the NICU.




Figure 1. Amniotic fluid rises in both groups during 2 weeks treatment.

Footnotes

Authors' Contribution: Leila Torkashvand: Conceived and designed the evaluation and drafted the manuscript, re-analyzed the clinical and statistical data and revised the manuscript; Shahla Nasrolahi: Collected the clinical data, interpreted them and revised the manuscript; Elaheh Talebi-Ghane: Participated in designing the evaluation, performed the statistical analysis and helped to draft the manuscript. All authors read and approved the final manuscript.

Clinical Trial Registration Code: IRCT20220903055868N1.

Conflict of Interests: Funding or research support: No;

employment: No; personal financial interests: No; stocks or shares in companies: No; consultation fees: No; patents: No; personal or professional relations with organizations and individuals (parents and children, wife and husband, family relationships, etc.): No; unpaid membership in a government or non-governmental organization: No; are you one of the editorial board members or a reviewer of this journal? No.

Ethical Approval: The study's conduct was approved by the Hamedan University of Medical Sciences' Ethics Committee ([IR.UMSHA.REC.1401.361](https://doi.org/10.30611/IR.UMSHA.REC.1401.361)).

Funding/Support: This research project was approved in the form of a residency thesis under the financial support

of Hamedan University of Medical Sciences.

Informed Consent: Informed consent was obtained from each participant before enrolling in the study.

References

- De Bie FR, Basurto D, Kumar S, Deprest J, Russo FM. Sildenafil during the 2nd and 3rd Trimester of Pregnancy: Trials and Tribulations. *Int J Environ Res Public Health*. 2022;**19**(18):11207. [PubMed ID: 36141480]. [PubMed Central ID: PMC9517616]. <https://doi.org/10.3390/ijerph191811207>.
- Whittington JR, Ghahremani T, Friski A, Hamilton A, Magann EF. Window to the Womb: Amniotic Fluid and Postnatal Outcomes. *Int J Womens Health*. 2023;**15**:117–24. [PubMed ID: 36756186]. [PubMed Central ID: PMC9900144]. <https://doi.org/10.2147/IJWH.S378020>.
- Brace RA, Cheung CY, Anderson DF. Regulation of amniotic fluid volume: insights derived from amniotic fluid volume function curves. *Am J Physiol Regul Integr Comp Physiol*. 2018;**315**(4):R777–89. [PubMed ID: 30024777]. [PubMed Central ID: PMC6230884]. <https://doi.org/10.1152/ajpregu.00175.2018>.
- Suliburska J, Kocylowski R, Komorowicz I, Grzesiak M, Bogdanski P, Baralkiewicz D. Concentrations of Mineral in Amniotic Fluid and Their Relations to Selected Maternal and Fetal Parameters. *Biol Trace Elem Res*. 2016;**172**(1):37–45. [PubMed ID: 26547910]. [PubMed Central ID: PMC4893386]. <https://doi.org/10.1007/s12011-015-0557-3>.
- Budunoglu MD, Yapca OE, Yildiz GA, Atakan Al R. Fetal renal blood flow velocimetry and cerebro-placental ratio in patients with isolated oligohydramnios. *J Gynecol Obstet Hum Reprod*. 2019;**48**(7):495–9. [PubMed ID: 31176048]. <https://doi.org/10.1016/j.jogoh.2019.06.002>.
- Molla M, Mengistu Z, Tsehaye W, Sisay G. Magnitude and associated factors of adverse perinatal outcomes among women with oligohydramnios at 3rd trimester at University of Gondar comprehensive specialized hospital, North West Ethiopia. *Front Glob Womens Health*. 2022;**3**:958617. [PubMed ID: 36793357]. [PubMed Central ID: PMC9922714]. <https://doi.org/10.3389/fgwh.2022.958617>.
- Morris RK, Meller CH, Tamblyn J, Malin GM, Riley RD, Kilby MD, et al. Association and prediction of amniotic fluid measurements for adverse pregnancy outcome: systematic review and meta-analysis. *BJOG*. 2014;**121**(6):686–99. [PubMed ID: 24738894]. <https://doi.org/10.1111/1471-0528.12589>.
- Hughes DS, Magann EF. Antenatal fetal surveillance "Assessment of the AFV". *Best Pract Res Clin Obstet Gynaecol*. 2017;**38**:12–23. [PubMed ID: 27756534]. <https://doi.org/10.1016/j.bpobgyn.2016.08.004>.
- Petrozella LN, Dashe JS, McIntire DD, Leveno KJ. Clinical significance of borderline amniotic fluid index and oligohydramnios in preterm pregnancy. *Obstet Gynecol*. 2011;**117**(2 Pt 1):338–42. [PubMed ID: 21252747]. <https://doi.org/10.1097/AOG.0b013e3182056766>.
- Rabie N, Magann E, Steelman S, Ounpraseuth S. Oligohydramnios in complicated and uncomplicated pregnancy: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2017;**49**(4):442–9. [PubMed ID: 27062200]. <https://doi.org/10.1002/uog.15929>.
- Choi SR. Borderline amniotic fluid index and perinatal outcomes in the uncomplicated term pregnancy. *J Matern Fetal Neonatal Med*. 2016;**29**(3):457–60. [PubMed ID: 25626056]. <https://doi.org/10.3109/14767058.2015.1004051>.
- Sahin E, Madendag Y, Tayyar AT, Sahin ME, Col Madendag I, Acmaz G, et al. Perinatal outcomes in uncomplicated late preterm pregnancies with borderline oligohydramnios. *J Matern Fetal Neonatal Med*. 2018;**31**(23):3085–8. [PubMed ID: 28782398]. <https://doi.org/10.1080/14767058.2017.1364722>.
- Hou L, Wang X, Hellerstein S, Zou L, Ruan Y, Zhang W. Delivery mode and perinatal outcomes after diagnosis of oligohydramnios at term in China. *J Matern Fetal Neonatal Med*. 2020;**33**(14):2408–14. [PubMed ID: 30486718]. <https://doi.org/10.1080/14767058.2018.1553944>.
- Ganla KN, Choudhary RA, Desai KN, Kadam SB, Arunachalam K. A retrospective interventional study for evaluation of efficacy and safety of sildenafil citrate in improving intrauterine growth restriction and oligohydramnios using ultrasound Doppler velocimetry. *Int J Basic Clin Pharmacol*. 2019;**8**(12):2736. <https://doi.org/10.18203/2319-2003.ijbcp20195288>.
- Yin H, Zhao L, Lin Y, Wang Y, Hu Y, Sun G, et al. Perinatal outcomes following labor induction with dinoprostone in pregnancies with borderline amniotic fluid index at term: A clinical observation study. *J Obstet Gynaecol Res*. 2018;**44**(8):1397–403. [PubMed ID: 29932485]. <https://doi.org/10.1111/jog.13682>.
- Dunn L, Greer R, Flenady V, Kumar S. Sildenafil in Pregnancy: A Systematic Review of Maternal Tolerance and Obstetric and Perinatal Outcomes. *Fetal Diagn Ther*. 2017;**41**(2):81–8. [PubMed ID: 27926905]. <https://doi.org/10.1159/000453062>.
- Turner JM, Russo F, Deprest J, Mol BW, Kumar S. Phosphodiesterase-5 inhibitors in pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes. *BJOG*. 2022;**129**(11):1817–31. [PubMed ID: 35352868]. <https://doi.org/10.1111/1471-0528.17163>.
- Takahashi Y, Iwagaki S, Chiaki R, Iwasa T, Takenaka M, Kawabata I, et al. Amniocentesis before 26 weeks' gestation for severe fetal growth restriction with oligohydramnios: preliminary pilot study. *J Obstet Gynaecol Res*. 2014;**40**(3):677–85. [PubMed ID: 24245667]. <https://doi.org/10.1111/jog.12224>.
- Gizzo S, Noventa M, Vitagliano A, Dall'Asta A, D'Antona D, Aldrich CJ, et al. An Update on Maternal Hydration Strategies for Amniotic Fluid Improvement in Isolated Oligohydramnios and Normohydramnios: Evidence from a Systematic Review of Literature and Meta-Analysis. *PLoS One*. 2015;**10**(12):e0144334. [PubMed ID: 26658482]. [PubMed Central ID: PMC4684238]. <https://doi.org/10.1371/journal.pone.0144334>.
- Kiran S, Ameen A, Akram A, Jamil M. Comparison of effects of oral maternal hydration and intravenous infusions on Amniotic Fluid Index in third trimester isolated Oligohydramnios. *Prof Med J*. 2019;**26**(12):2064–9. <https://doi.org/10.29309/tpmj/2019.26.12.3049>.
- El-Sayed MA, Saleh SA, Maher MA, Khidre AM. Utero-placental perfusion Doppler indices in growth restricted fetuses: effect of sildenafil citrate. *J Matern Fetal Neonatal Med*. 2018;**31**(8):1045–50. [PubMed ID: 28345432]. <https://doi.org/10.1080/14767058.2017.1306509>.
- Choudhary R, Desai K, Parekh H, Ganla K. Sildenafil citrate for the management of fetal growth restriction and oligohydramnios. *Int J Womens Health*. 2016;**8**:367–72. [PubMed ID: 27563258]. [PubMed Central ID: PMC4984996]. <https://doi.org/10.2147/IJWH.S108370>.
- Maher MA, Sayyed TM, Elkhoully N. Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. *Obstet Gynecol*. 2017;**129**(4):615–20. [PubMed ID: 28277352]. <https://doi.org/10.1097/AOG.0000000000001928>.
- Nath J, Chaube S, Rani N, Verma P. A study on sildenafil citrate in the treatment of IUGR & Oligohydramnios. *Investig Gynecol Res Womens Health*. 2021;**4**(2):312–4.